These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 16762647)

  • 21. Attachment disorder: a decline in the performance of the Bravo pH system.
    Francis DL
    Am J Gastroenterol; 2008 Oct; 103(10):2663. PubMed ID: 18855870
    [No Abstract]   [Full Text] [Related]  

  • 22. Esophageal impedance-pH monitoring.
    Sifrim D; Fornari F
    Dig Liver Dis; 2008 Mar; 40(3):161-6. PubMed ID: 18082474
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reflux monitoring: pH-metry, Bilitec and oesophageal impedance measurements.
    Pohl D; Tutuian R
    Best Pract Res Clin Gastroenterol; 2009; 23(3):299-311. PubMed ID: 19505660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of prolonged pH measurements on the diagnosis of gastroesophageal reflux disease: 4-day wireless pH studies.
    Scarpulla G; Camilleri S; Galante P; Manganaro M; Fox M
    Am J Gastroenterol; 2007 Dec; 102(12):2642-7. PubMed ID: 17850412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and tolerability of BRAVO capsule pH monitoring.
    Tankurt E; Tüzömay N; Sengül B; Kinik E; Açil B
    Turk J Gastroenterol; 2011 Jun; 22(3):352-3. PubMed ID: 21805432
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparison of wireless 48-h (Bravo) versus traditional ambulatory 24-h esophageal pH monitoring.
    Håkanson BS; Berggren P; Granqvist S; Ljungqvist O; Thorell A
    Scand J Gastroenterol; 2009; 44(3):276-83. PubMed ID: 19040176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CON: Treatment with PPIs should not be preceded by pH monitoring in patients suspected of laryngeal reflux.
    Vaezi MF
    Am J Gastroenterol; 2006 Jan; 101(1):8-10. PubMed ID: 16405526
    [No Abstract]   [Full Text] [Related]  

  • 28. Accuracy and tolerability of the Bravo catheter-free pH capsule in patients between the ages of 4 and 18 years.
    Croffie JM; Fitzgerald JF; Molleston JP; Gupta SK; Corkins MR; Pfefferkorn MD; Lim JR; Steiner SJ; Dadzie SK
    J Pediatr Gastroenterol Nutr; 2007 Nov; 45(5):559-63. PubMed ID: 18030233
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bravo capsule for wireless 48-h pH monitoring: proposed algorithm for its placement.
    Marchese M; Spada C; Costamagna G
    Am J Gastroenterol; 2007 Sep; 102(9):2104-5; author reply 2106. PubMed ID: 17727439
    [No Abstract]   [Full Text] [Related]  

  • 30. Interference with daily activities and major adverse events during esophageal pH monitoring with bravo wireless capsule versus conventional intranasal catheter: a systematic review of randomized controlled trials.
    Iluyomade A; Olowoyeye A; Fadahunsi O; Thomas L; Libend CN; Ragunathan K; Fenster J; Vignesh S
    Dis Esophagus; 2017 Feb; 30(3):1-9. PubMed ID: 26952638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An unusual case of Bravo capsule aspiration.
    von Renteln D; Kayser T; Riecken B; Caca K
    Endoscopy; 2008 Sep; 40 Suppl 2():E174. PubMed ID: 18668461
    [No Abstract]   [Full Text] [Related]  

  • 32. [Diagnostic advances in gastroesophageal reflux disease].
    Valdovinos Díaz MA
    Rev Gastroenterol Mex; 2006 Aug; 71 Suppl 1():56-9. PubMed ID: 17037773
    [No Abstract]   [Full Text] [Related]  

  • 33. Esophageal pH monitoring goes wireless.
    Lawrence BL; Taylor D
    Nursing; 2007 Oct; 37(10):26-7. PubMed ID: 17906527
    [No Abstract]   [Full Text] [Related]  

  • 34. Control of esophageal and intragastric pH with compounded and manufactured omeprazole in patients with reflux esophagitis: a pilot study.
    Moretzsohn LD; Carvalho EB; Franco JD; Soares MP; Brito EM; Belarmino K; Coelho LG
    Can J Clin Pharmacol; 2009; 16(1):e264-72. PubMed ID: 19383986
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 48-hour wireless oesophageal pH-monitoring in children: are two days better than one?
    Gunnarsdóttir A; Stenström P; Arnbjörnsson E
    Eur J Pediatr Surg; 2007 Dec; 17(6):378-81. PubMed ID: 18072019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Significant enhancement of esophageal pre-epithelial defense by tegaserod: implications for an esophagoprotective effect.
    Majewski M; Jaworski T; Sarosiek I; Sostarich S; Roeser K; Edlavitch SA; Kralstein J; Wallner G; McCallum RW; Sarosiek J
    Clin Gastroenterol Hepatol; 2007 Apr; 5(4):430-8. PubMed ID: 17445751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expert commentary: a multicenter study to define the incidence of short esophagus in surgical patients with gastroesophageal reflux disease.
    Pearson FG
    J Thorac Cardiovasc Surg; 2008 Oct; 136(4):842. PubMed ID: 18954620
    [No Abstract]   [Full Text] [Related]  

  • 38. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: 'on' or 'off' proton pump inhibitor?
    Hemmink GJ; Bredenoord AJ; Weusten BL; Monkelbaan JF; Timmer R; Smout AJ
    Am J Gastroenterol; 2008 Oct; 103(10):2446-53. PubMed ID: 18684197
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new pH catheter for laryngopharyngeal reflux: Normal values.
    Sun G; Muddana S; Slaughter JC; Casey S; Hill E; Farrokhi F; Garrett CG; Vaezi MF
    Laryngoscope; 2009 Aug; 119(8):1639-43. PubMed ID: 19504553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and tolerability of transoral Bravo capsule placement after transnasal manometry using a validated conversion factor.
    Lacy BE; O'Shana T; Hynes M; Kelley ML; Weiss JE; Paquette L; Rothstein RI
    Am J Gastroenterol; 2007 Jan; 102(1):24-32. PubMed ID: 17100980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.